Key result
Perioperative levosimendan fails to improve survival in cardiac surgery patients.
Why the study?
Does perioperative levosimendan infusion reduce mortality and low cardiac output syndrome in patients undergoing cardiac surgery?
Does perioperative levosimendan infusion reduce mortality and low cardiac output syndrome in patients undergoing cardiac surgery?
Routine perioperative levosimendan administration cannot be recommended to reduce mortality in heart surgery patients, despite its potential to reduce low cardiac output syndrome.
No takes yet. Share an insight, caveat, or question.
Levosimendan should not be used routinely in cardiac surgery; confirms recent large RCTs and challenges earlier positive meta-analyses of small trials.
Santillo et al. (2018) conducted a review in Cardiac surgery. Levosimendan vs. Placebo or other inotropes was evaluated. Recent large randomized controlled trials demonstrate that perioperative levosimendan does not provide significant survival benefits and cannot be recommended as standard therapy for patients undergoing cardiac surgery.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: